American Association for Cancer Research
15357163mct140801-sup-137941_2_supp_3037138_nqkm7l.doc (28 kB)

Supplementary Table 3 from Targeting c-MYC in Platinum-Resistant Ovarian Cancer

Download (28 kB)
journal contribution
posted on 2023-04-03, 14:28 authored by Jeyshka M. Reyes-González, Guillermo N. Armaiz-Peña, Lingegowda S. Mangala, Fatma Valiyeva, Cristina Ivan, Sunila Pradeep, Ileabett M. Echevarría-Vargas, Adrian Rivera-Reyes, Anil K. Sood, Pablo E. Vivas-Mejía

Shelf-life of lyophilized 50% cholesterol DOPC-PEG-siRNA nanoliposomes stored at 4oC.



The purpose of this study was to investigate the molecular and therapeutic effects of siRNA-mediated c-MYC silencing in cisplatin-resistant ovarian cancer. Statistical analysis of patient's data extracted from The Cancer Genome Atlas (TCGA) portal showed that the disease-free (DFS) and the overall (OS) survival were decreased in ovarian cancer patients with high c-MYC mRNA levels. Furthermore, analysis of a panel of ovarian cancer cell lines showed that c-MYC protein levels were higher in cisplatin-resistant cells when compared with their cisplatin-sensitive counterparts. In vitro cell viability, growth, cell-cycle progression, and apoptosis, as well as in vivo therapeutic effectiveness in murine xenograft models, were also assessed following siRNA-mediated c-MYC silencing in cisplatin-resistant ovarian cancer cells. Significant inhibition of cell growth and viability, cell-cycle arrest, and activation of apoptosis were observed upon siRNA-mediated c-MYC depletion. In addition, single weekly doses of c-MYC–siRNA incorporated into 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG-2000)-based nanoliposomes resulted in significant reduction in tumor growth. These findings identify c-MYC as a potential therapeutic target for ovarian cancers expressing high levels of this oncoprotein. Mol Cancer Ther; 14(10); 2260–9. ©2015 AACR.